Phase 3 N=112 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -0.8 days — p==0.0232
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=414 A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Chronic Renal Failure Requiring Hemodialysis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1 — 13.0 Percentage of participants
Phase 3 N=40 Gabapentin for Abstinence Initiation in Alcohol Dependence
Alcohol Dependence
Primary: Percent of Heavy Drinking Days Per Week — 22.5; 53.9 percent of heavy drinking days
Phase 3 N=162 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
Plaque Psoriasis
Primary: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24 — 90.7; 22.2; 70.4 Percentage of Participants — p=<.0001
Phase 3 N=63 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids
Eosinophilic Esophagitis · Eosinophilic Gastrointestinal Disorders (EGIDs)
Primary: Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks — -14.3; -21.6 units on a scale — p=0.04
Phase 3 N=559 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
Psoriasis · Plaque Psoriasis
Primary: Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 5.0; 53.3; 61.3; 66.7 percentage of participants — p=<0.0001
Phase 3 N=206 ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) · Amyloidosis, Hereditary · Amyloid Neuropathies, Familial
Primary: 6 Minute Walk Distance (6-MWD)
Phase 3 N=102 Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics
Liver Transplantation · Surgical Site Infection
Primary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants
Phase 3 N=546 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Overall Survival — 3.6; 3.5 years
Phase 3 N=274 Eslicarbazepine Acetate Monotherapy Long Term Study
Epilepsy
Primary: Number and Percent of Subjects With Treatment Emergent Adverse Events — 220 Participants
Phase 3 N=119 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.2 percentage of participants
Phase 3 N=75 Treatment of Mania Symptoms With Drug Therapy
Bipolar Disorder · Schizophrenia
Primary: Symptoms of Mania, as Measured by Young Mania Rating Scale — 5.7; 11.1; 10.0 units on a scale
Phase 3 N=199 The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Infections, Papillomavirus
Primary: Number of Subjects Reporting Serious Adverse Events — 6; 2; 0 Participants
Phase 3 N=275 Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
HIV-1 Infection
Primary: Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24 — 93.4; 97.8; 96.6 percentage of participants — p=0.15
Phase 3 N=28 Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents
Anaemia
Primary: Change From Baseline in Hgb at Week 4 — 0.79 G/dL